Tissue Expander Magnetic Valve Inflation — PatSnap Eureka
Tissue Expander Magnetic Valve Inflation Patents
Remote-controlled magnetic valve inflation eliminates percutaneous needle injections in breast and soft tissue reconstruction. This dataset spans smart self-filling expanders, sensor-integrated monitoring, and magnetically programmable valve analogues.
From Needle Injections to Transcutaneous Programmable Expansion
Tissue expander remote-controlled magnetic valve inflation uses an implantable saline reservoir with an internally housed valve that responds to an external magnetic or electromagnetic stimulus, permitting controlled inflation without percutaneous needle access. This eliminates repeated clinic visits for saline injections during breast and soft tissue reconstruction.
Within this dataset, three intersecting technology bodies are represented: smart self-filling tissue expander systems for breast reconstruction, sensor-integrated implantable expanders with wireless patient monitoring, and adjacent magnetically programmable implanted valve mechanisms drawn from the neurosurgical shunt field.
The Blossom smart expander pilot study (2020) documented mean time to full expansion of 11.7–13.4 days and a major complication rate of only 4.5% across 22 expanders, representing the most directly on-topic clinical evidence in the dataset. This signals approaching commercial readiness for pressure-responsive self-filling systems.
In this dataset, no single dominant commercial breast implant OEM appears with dedicated magnetic valve tissue expander patents. One academic assignee — Research & Business Foundation Sungkyunkwan University — holds the most technically advanced recent filing (EP, 2025) in retrieved records, reflecting emerging Korean academic-to-commercial IP activity.
Patent Activity and Innovation Signals Across the Dataset
The retrieved records span 2006 to 2025, capturing a progression from inflatable multi-chamber valve architectures through clinical self-filling expander pilots to sensor-integrated smart expanders with patient connectivity. The following charts map assignee activity and technology timeline within this dataset.
Patent Records by Named Assignee (Dataset Snapshot)
In this dataset, DFM LLC and Research & Business Foundation Sungkyunkwan University each account for the largest identifiable blocks of named-assignee filings, with DFM holding two continuation records in the inflatable chamber cluster.
↗ Click bars to exploreTechnology Innovation Timeline by Filing/Publication Year
In this dataset, filing and publication activity spans 2006 to 2025, with a concentration of adjacent inflatable valve architecture patents in 2006–2013 and the most recent tissue expander-specific sensor-integrated patent appearing in 2025.
↗ Click bars to exploreKey Application Areas for Magnetic Valve Inflation Technology
The retrieved dataset identifies three primary application domains: breast reconstruction and augmentation as the core clinical target, soft tissue and craniofacial reconstruction as an adjacent domain, and neurosurgical shunt valves as the established technology analogue domain. A fourth adjacent domain covers inflatable implant valve architectures from cardiac and orthopedic surgery.
Breast Reconstruction Post-Mastectomy
The primary evidenced application domain in this dataset. The Blossom smart expander pilot (2020) enrolled 14 patients across 22 expanders, achieving mean full expansion in 11.7–13.4 days with a 4.5% major complication rate across implant-based and combined flap modalities. The Sungkyunkwan University EP patent (2025, active) adds MMP biosensor-based capsular contracture monitoring with a linked patient information system to this domain.
Clinical ReconstructionNeurosurgical Hydrocephalus Shunt Valves
Externally programmable cerebrospinal fluid shunt valves constitute the most mature implementation of remote magnetic valve actuation in implanted devices. A 2012 study on 3T MRI exposure of first- and second-generation EPS-valves established that first-generation valves are susceptible to unintended magnetic reprogramming, while second-generation locking mechanisms resist it — directly informing tissue expander magnetic valve design requirements including MRI safety validation.
Neurosurgical AnalogueCardiac and Vascular Inflatable Implants
DFM, LLC holds two US patents (2006, inactive; 2013, inactive) on methods of in situ formation of translumenally deployable heart valve support structures featuring independently inflatable first and second chambers. This multi-chamber sequential inflation architecture directly parallels staged tissue expansion mechanisms, providing a foundational IP precedent for remotely controlled multi-chamber saline expanders.
Adjacent Valve ArchitectureSoft Tissue and Craniofacial Reconstruction
Beyond breast reconstruction, tissue expanders are used for scalp, facial, and limb reconstruction. Remote inflation capability addresses particular clinical needs in pediatric patients where repeated percutaneous injections are distressing and anatomical port access is limited. No craniofacial-specific patents were retrieved in this dataset, but the neurosurgical shunt valve magnetic programmability literature (2012) directly informs this sub-domain given shared pediatric hydrocephalus patient populations.
Reconstructive SurgeryKey Patent Assignees in Tissue Expander Magnetic Valve Inflation (Retrieved Records)
In this dataset, Research & Business Foundation Sungkyunkwan University holds the most recent and technically advanced tissue expander patent (EP, 2025, active), while DFM, LLC accounts for two records in retrieved records via its inflatable multi-chamber cardiac implant continuation patents (US, 2006 and 2013, both inactive). No major breast implant OEM appears in this dataset with dedicated tissue expander magnetic valve filings.
Patent Records by Named Assignee — Tissue Expander Magnetic Valve Dataset (Dataset Snapshot)
↗ Click bars to exploreResearch & Business Foundation Sungkyunkwan University
Holds 1 active patent in retrieved records: EP patent published February 2025 covering a tissue expander for breast reconstruction with real-time MMP sensor-based capsular contracture monitoring, integrated treatment capabilities, and a linked patient information system. This is the most technically advanced and most recent tissue expander-specific patent in this dataset, combining biochemical sensing, wireless data transmission, and closed-loop treatment response in a single device architecture.
South Korea — EP filingDFM, LLC
Holds 2 records in retrieved records: a US patent filed in 2006 (inactive) and a 2013 continuation (inactive) both describing methods of in situ formation of translumenally deployable heart valve support structures with independently inflatable first and second chambers. While focused on cardiac applications, the multi-chamber sequential inflation architecture directly parallels staged tissue expansion mechanisms and informs freedom-to-operate analysis for tissue expander developers.
United States — US filingFour Forward Directions in Smart Tissue Expander Technology
The most recent filings and publications (2020–2025) in this dataset point to four forward directions: biosensor-integrated smart expanders, patient-facing digital connectivity, MRI-safe locking valve mechanisms, and pressure-responsive rate control as an alternative to active magnetic triggering.
Biosensor-Integrated Closed-Loop Inflation Control
The Sungkyunkwan University EP patent (2025) introduces MMP-based capsular contracture detection directly into the expander body. The logical next step — using MMP sensor data to autonomously trigger or halt magnetic valve inflation — represents a closed-loop inflation control architecture not yet patented in the retrieved dataset. This sensor-fusion approach creates a multi-layer IP architecture substantially harder to design around than a standalone valve mechanism patent.
MRI-Safe Locking Mechanisms for Magnetic Valves
The 2012 shunt valve MRI study established that first-generation externally programmable valves are susceptible to unintended reprogramming at 3T MRI, while second-generation valves with locking mechanisms showed resistance. Given high-frequency post-mastectomy surveillance imaging requirements, MRI compatibility with a validated locking mechanism is an emerging mandatory design criterion for any breast expander magnetic valve entering development in 2025–2026.
Active Magnetic Valve Actuation vs. Pressure-Responsive Self-Filling
Click any row to explore further.
| Dimension | Active Magnetic Valve Actuation | Pressure-Responsive Self-Filling |
|---|---|---|
| Primary Mechanism | External magnetic or electromagnetic programmer actuates internal valve to admit saline on demand | Built-in pressure-relief/osmotic architecture drives saline fill at a controlled rate without external trigger |
| Key Dataset Evidence | Externally programmable shunt valve MRI study (2012); Sungkyunkwan University EP patent (2025) | Blossom smart expander pilot study (2020, 14 patients, 22 expanders) |
| Expansion Timeline | Not quantified in retrieved dataset for tissue expander-specific magnetic valve systems | Mean full expansion 11.7–13.4 days in Blossom pilot |
| Physician Control | High — physician or patient app initiates each inflation event on schedule | Lower — fill rate is autonomous; physician sets initial system parameters |
| MRI Compatibility Challenge | High — first-generation magnetic valves susceptible to unintended reprogramming at 3T MRI | Not identified as a primary concern in retrieved Blossom records |
| Sensor Integration | Sungkyunkwan EP (2025) adds MMP biosensors for capsular contracture detection linked to patient information system | Pressure-responsive mechanism; no biosensor integration documented in retrieved records |
| IP Status in Dataset | Sungkyunkwan EP patent active (2025); shunt valve analogue literature only (2012) | Blossom documented as clinical literature (2020); no direct patent record retrieved |
| Complication Rate | Not reported for magnetic valve tissue expanders in retrieved records | 4.5% major complication rate across 22 expanders in Blossom pilot |
Frequently Asked Questions: Tissue Expander Magnetic Valve Inflation Patents
The core mechanism unites an implantable saline reservoir with an internally housed valve that responds to an external magnetic or electromagnetic stimulus, permitting controlled inflation without percutaneous needle access. Reprogramming is achieved by placing an external programmer containing a permanent or electromagnet over the implant site, analogous to externally programmable cerebrospinal fluid shunt valves used in hydrocephalus treatment.
The Blossom smart expander pilot study (2020) enrolled 14 patients across 22 expanders in both implant-based and combined flap breast reconstruction modalities. It documented mean time to full expansion of 11.7–13.4 days and a major complication rate of only 4.5%, demonstrating clinical feasibility without percutaneous needle injections.
Research & Business Foundation Sungkyunkwan University holds an EP patent published in February 2025 (active status) covering a tissue expander for breast reconstruction with real-time MMP biosensor-based capsular contracture monitoring, integrated treatment capabilities, and a linked patient information system. This is the most recent and technically sophisticated tissue expander-specific patent in the retrieved dataset.
Externally programmable cerebrospinal fluid shunt valves — used in hydrocephalus treatment — represent the most mature validated implementation of remote magnetic actuation in implanted valves. A 2012 study on 3T MRI testing of these valves established that first-generation designs are susceptible to unintended reprogramming by magnetic fields, while second-generation locking mechanisms resist it. These design challenges — MRI compatibility and locking mechanisms — are directly applicable to tissue expander magnetic valve development.
No major breast implant OEM such as Allergan/AbbVie, Mentor/J&J, or Sientra appears in this dataset with dedicated tissue expander remote magnetic valve patents. The dataset suggests either that such filings exist outside the retrieved corpus or that commercial development is occurring through acquisition rather than internal R&D patent filing.
Evidence from the 2012 shunt valve MRI study confirms that first-generation magnetically programmable valves are vulnerable to unintended setting changes in 3T MRI environments. Any tissue expander magnetic valve entering development in 2025–2026 must incorporate a validated locking mechanism and demonstrate MRI safety, or it will face regulatory and clinical adoption barriers — particularly given the high frequency of post-mastectomy surveillance imaging.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.